CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
Orticumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04776629
NCT04776629Phase 2Completed
CompareCT.gov

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

Abcentra·interventional·Posted Mar 2, 2021·Updated May 11, 2026

In Brief

A Phase 2 clinical trial evaluating Orticumab and Placebo for Psoriasis and 3 related conditions. Completed, enrolled 77 participants across 13 sites.

Detailed Summary

The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 2, 2021
Enrollment StartJun 30, 2021
Primary CompletionNov 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.3 years ago

Interventions

Orticumabdrug

A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope

Placebodrug

Placebo for orticumab, containing all components of formulation except the active ingredient